Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report issued on Monday morning,Benzinga reports. They currently have a $15.00 price objective on the stock.

Several other analysts have also recently weighed in on the stock. Chardan Capital reissued a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, February 2nd. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Coya Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Coya Therapeutics Trading Down 0.7%

Shares of COYA stock opened at $4.50 on Monday. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $7.75. The company’s 50-day moving average price is $4.75 and its 200-day moving average price is $5.58. The stock has a market cap of $94.14 million, a price-to-earnings ratio of -4.05 and a beta of 0.23.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The firm had revenue of $3.96 million for the quarter, compared to analyst estimates of $1.93 million. As a group, equities research analysts predict that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Alyeska Investment Group L.P. acquired a new stake in shares of Coya Therapeutics during the fourth quarter valued at about $4,640,000. AWM Investment Company Inc. acquired a new position in shares of Coya Therapeutics in the 4th quarter worth approximately $4,205,000. CM Management LLC boosted its position in shares of Coya Therapeutics by 16.7% during the 4th quarter. CM Management LLC now owns 350,000 shares of the company’s stock worth $2,030,000 after purchasing an additional 50,000 shares during the period. Private Management Group Inc. purchased a new position in shares of Coya Therapeutics during the 4th quarter worth approximately $1,626,000. Finally, Marshall Wace LLP increased its holdings in Coya Therapeutics by 438.8% in the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock valued at $1,307,000 after purchasing an additional 183,533 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.